Premium
The utility of multiparametric seven‐color flow cytometry in the detection of double hit lymphoma in ascitic fluid samples
Author(s) -
Cordoba Raul,
Alvarez Beatriz,
Masso Pilar,
Gonzalez Fernando Ataulfo,
Conejo Luz,
Velasco Diego,
Alonso JuanManuel,
Villarrubia Jesus,
Cava Fernando,
Llamas Pilar
Publication year - 2016
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21227
Subject(s) - immunophenotyping , fluorescence in situ hybridization , lymphoma , flow cytometry , cd38 , pathology , cd5 , immunoglobulin light chain , cd20 , bcl6 , cd43 , diffuse large b cell lymphoma , cd19 , mantle cell lymphoma , cytometry , medicine , microbiology and biotechnology , b cell , biology , antibody , immunology , cd34 , germinal center , biochemistry , genetics , stem cell , chromosome , gene
Double‐hit lymphoma (DHL) is a rare type of lymphoma with concurrent chromosomal translocations of C‐MYC with BCL2 or BCL6, associated with unfavorable prognosis. We describe a case of DHL in a 79‐year‐old female patient previously diagnosed with diffuse large B‐cell lymphoma (DLBCL) with an early relapse in the ascitic fluid. A seven‐color multiparametric flow cytometry immunophenotyping study of the ascitic fluid was carried out, and revealed 99.78% of large in size and high cellular complexity B‐cells positive for CD19, CD10 (64.27%), CD45 dim, CD22 dim, CD25 (60%), CD43 bright, CD38 bright, and IgM (18.53%); and negative for CD20, CD5, CD23, CD79b, CD103, CD200, CD11c, and FMC7, and 78.99% without light chain expression and 21% with Lambda chain restriction. Due to the expression of CD19 and CD10 with overexpression of BCL‐2 protein and due to CD43 and CD38 positivity detected, those cells showed features between DLBCL and Burkitt lymphoma. Fluorescence in situ hybridization (FISH) confirmed both c‐MYC/IGH and BCL2/IGH rearrangement. Our findings may help to identify cases requiring additional cytogenetic analysis. © 2015 International Clinical Cytometry Society